Taylor Financial Group Inc. Grows Stock Holdings in Pfizer Inc. $PFE

Taylor Financial Group Inc. raised its position in Pfizer Inc. (NYSE:PFE) by 25.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,806 shares of the biopharmaceutical company’s stock after acquiring an additional 2,815 shares during the quarter. Taylor Financial Group Inc.’s holdings in Pfizer were worth $335,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Capital Advisory Group Advisory Services LLC lifted its holdings in Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares during the period. Citizens National Bank Trust Department raised its holdings in shares of Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 395 shares in the last quarter. Trust Co of the South raised its holdings in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after acquiring an additional 441 shares in the last quarter. Charter Oak Capital Management LLC raised its holdings in shares of Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after acquiring an additional 444 shares in the last quarter. Finally, Ballentine Partners LLC increased its position in Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after purchasing an additional 458 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PFE. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.13.

Pfizer Stock Performance

Pfizer stock opened at $24.76 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $140.75 billion, a P/E ratio of 13.17, a PEG ratio of 0.82 and a beta of 0.55. The stock’s 50 day moving average is $24.86 and its 200 day moving average is $24.21. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.